相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms
Martin Y. Ng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene
Arianna Venturini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Integrity and Stability of PTC Bearing CFTR mRNA and Relevance to Future Modulator Therapies in Cystic Fibrosis
Luka A. Clarke et al.
GENES (2021)
Effect of small molecule eRF3 degraders on premature termination codon readthrough
Alireza Baradaran-Heravi et al.
NUCLEIC ACIDS RESEARCH (2021)
Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators
Gisele Nishiguchi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion
Jyoti Sharma et al.
NATURE COMMUNICATIONS (2021)
Effect of small molecule eRF3 degraders on premature termination codon readthrough
Alireza Baradaran-Heravi et al.
NUCLEIC ACIDS RESEARCH (2021)
Divergent effects of translation termination factor eRF3A and nonsense-mediated mRNA decay factor UPF1 on the expression of uORF carrying mRNAs and ribosome protein genes
Affaf Aliouat et al.
RNA BIOLOGY (2020)
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action
Onofrio Laselva et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)
M. W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
CC-90009, a novel cereblon E3 ligase modulator targets acute myeloid leukemia blasts and leukemia stem cells
Christine Surka et al.
BLOOD (2020)
Extent of rescue of F508de1-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients
Arthur Kmit et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2019)
Decreased mRNA and protein stability of W1282X limits response to modulator therapy
M. A. Aksit et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations
Lulu Huang et al.
NUCLEIC ACID THERAPEUTICS (2019)
CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)
Antonia Lopez-Girona et al.
BLOOD (2019)
Pharmacodynamic Responses to CC90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Jinhong Fan et al.
BLOOD (2019)
A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1
Liqing Jin et al.
BLOOD (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen
Gang Lu et al.
BLOOD (2019)
Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study
Geoffrey L. Uy et al.
BLOOD (2019)
Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells
Hillary C. Valley et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Chronic E-Cigarette Exposure Alters the Human Bronchial Epithelial Proteome
Arunava Ghosh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
Scott H. Donaldson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
Maciej Dabrowski et al.
MOLECULAR MEDICINE (2018)
Structure-guided combination therapy to potently improve the function of mutant CFTRs
Guido Veit et al.
NATURE MEDICINE (2018)
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis
Ren-Jay Shei et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine
Nikhil T. Awatade et al.
FRONTIERS IN PHARMACOLOGY (2018)
Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies
John J. Brewington et al.
JCI INSIGHT (2018)
The US Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial
Anthony G. Durmowicz et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2018)
Correctors and Potentiators Rescue Function of the Truncated W1282X-Cystic Fibrosis Transmembrane Regulator ( CFTR) Translation Product*
Peter M. Haggie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
Venkateshwar Mutyam et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
Xuefeng Liu et al.
NATURE PROTOCOLS (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Jennifer L. Taylor-Cousar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Conditional reprogramming of pediatric airway epithelial cells: A new human model to investigate early-life respiratory disorders
S. Wolf et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2017)
High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations
Feng Liang et al.
SLAS TECHNOLOGY (2017)
Conservation of Nonsense-Mediated mRNA Decay Complex Components Throughout Eukaryotic Evolution
Barry Causier et al.
SCIENTIFIC REPORTS (2017)
Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells
Martina Gentzsch et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2017)
BMI-1 extends proliferative potential of human bronchial epithelial cells while retaining their mucociliary differentiation capacity
Mustafa M. Munye et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2017)
Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770
Martina Gentzsch et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2016)
Airway Progenitor Clone Formation Is Enhanced by Y-27632-Dependent Changes in the Transcriptome
Susan D. Reynolds et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2016)
Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)
Kerstin Nagel-Wolfrum et al.
BIODRUGS (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators
Wei Wang et al.
PLOS ONE (2016)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cystic fibrosis
Felix Ratjen et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Cystic fibrosis genetics: from molecular understanding to clinical application
Garry R. Cutting
NATURE REVIEWS GENETICS (2015)
Therapeutics Based on Stop Codon Readthrough
Kim M. Keeling et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 15 (2014)
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
Fredrick Van Goor et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
Kris De Boeck et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis
Deborah M. Cholon et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
When proteins start to make sense: fine-tuning of aminoglycosides for PTC suppression therapy
Moran Shalev et al.
MEDCHEMCOMM (2014)
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
Elton Kerem et al.
LANCET RESPIRATORY MEDICINE (2014)
Efficient Immortalization of Primary Nasopharyngeal Epithelial Cells for EBV Infection Study
Yim Ling Yip et al.
PLOS ONE (2013)
Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells
Frank A. Suprynowicz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
New developments in aminoglycoside therapy and ototoxicity
Jing Xie et al.
HEARING RESEARCH (2011)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Cystic Fibrosis Transmembrane Conductance Regulator Impedes Proteolytic Stimulation of the Epithelial Na+ Channel
Martina Gentzsch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Novel human bronchial epithelial cell lines for cystic fibrosis research
M. L. Fulcher et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Feasibility of nasal epithelial brushing for the study of airway epithelial functions in CF infants
Katharina Mosler et al.
JOURNAL OF CYSTIC FIBROSIS (2008)
HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function
Xuefeng Liu et al.
VIROLOGY (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin
Liat Linde et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Domain interdependence in the biosynthetic assembly of CFTR
Liying Cui et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
F Van Goor et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Regulation of blood pressure, the epithelial sodium channel (ENaC), and other key renal sodium transporters by chronic insulin infusion in rats
J Song et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2006)
Central role for ENaC in development of hypertension
JH Pratt
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Involvement of human release factors eRF3a and eRF3b in translation termination and regulation of the termination complex formation
C Chauvin et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
M Wilschanski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Stop codon suppression via inhibition of eRF1 expression
J Carnes et al.
RNA (2003)
A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
M Wilschanski et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
分享论文
